Infectious Diseases
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global pharma infectious disease market intelligence: track R&D, regulatory approvals, and investment trends for novel antivirals, antibacterials, and vaccines.
Showing 1–8 of 8 articles
Quick answer
NovaPharmaNews Infectious Diseases hub for FDA covers 8 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Eli Lilly's $3.8B Investment in Infectious Disease Portfolio
ANVISA Clinical Trial Changes Brazil: What You Need to Know
FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination
Emergent BioSolutions Partners with Substipharm for $34.5M Japanese Encephalitis Vaccine Manufacturing Deal
Novartis Coartem Baby Receives WHO Prequalification as First Malaria Treatment for Newborns
APHL 2026 Annual: Public Health Lab Trends in Baltimore
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
Elion Therapeutics Launches Phase 2 Trial for Turletricin (EL219) in Invasive Mold Infections
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.